One of the primary causes for drug failure in the development phase is poor pharmacokinetics and ADME (Absorption, Distribution, Metabolism, Excretion) properties. Utilizing high throughput (HT) workflows and fast ADME profiling assays that assess biopharmaceutical properties in parallel with efficacy data allows for the prioritization of lead compounds earlier in the discovery phase. This strategy will not only improve the quality and the probability of success of your lead candidate pool but also shorten the overall discovery and development timeline.
Charles River continues to add speed and efficiencies to early screening with a robust in vitro HT-ADME platform. The HT platform combines Hamilton liquid-handler automation with high-speed method development and ADDA-LC/MS/MS bioanalysis together with LIMS IT workflows to achieve a high capacity and ≤ 5 days turnaround from compound receipt to data delivery for the primary assays: metabolic stability, PPB, and permeability. The successful validation of the in vitro HT-ADME platform to meet the turnaround time demands of the industry is highlighted in this scientific poster.
To prevent adverse events related to drug metabolism, drug-drug interaction, and clearance later in development, improved in vitro assays now provide more efficient and effective ADME testing and PK/PD studies. Check out a recent webinar entitled Enabling DMPK Science to learn how in vitro ADME data can be delivered even faster and used for many purposes during the drug discovery and development process to triage and prioritize NCEs.